Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Detroit, Michigan 48201


The purpose of this study is to determine the safety and toxicity profile of TAK-593 and determine the maximum tolerated dose of TAK-593.


Inclusion Criteria: - ≥ 18 years of age diagnosed with advanced solid tumor cancer that failed to respond to standard therapies and where no other treatment options are available. - No prior chemotherapy - Able to understand and follow study requirements - Subject or subject's legal representative signs a written, informed consent form prior to beginning any study procedures. - Women who are post-menopausal for at least 1 year before screening or surgically sterile - Women of childbearing potential agree to practice two effective methods of birth control from the time of signing the informed consent form through 30 days after the last dose of the study drug or agree to completely abstain from heterosexual intercourse. - Men who agree to practice an effective method of birth control for the entire study treatment period and through 30 days after the last dose of study drug or completely agree to abstain from heterosexual intercourse. - Ability to swallow and retain oral medication - Meet study specific laboratory test standards for bone marrow function, liver function, blood pressure, and renal function. Exclusion Criteria: - Cancer has spread to the brain - History of another cancer diagnosed or treated within the past 3 years. - Severe cardiovascular issues including heart attack within the past 6 months, unstable angina or arrhythmias that require treatments. - Severe thyroid disease - Unstable angina - Arrhythmia issues - History of bleeding issues - Serious wounds, ulcers or bone fractures that do not heal - Subject is pregnant or breast feeding - Subject has illnesses or conditions that may affect their ability to participate in the study - Subject participated in another clinical study/post marketing clinical study within 4 weeks prior to the start of this trial.



Primary Contact:

Study Director
Medical Monitor
Millennium Pharmaceuticals, Inc.

Backup Contact:


Location Contact:

Detroit, Michigan 48201
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.